Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04924153 · ClinicalTrials.gov registry record
A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 35
- Enrollment target
NCT04924153 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 35 participants.
The verdict
NCT04924153 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
The primary objective of the study is to characterize seizures in participants with KCNT1-related epilepsy. The secondary objectives are to characterize head growth, symptom severity, neurocognitive and social functions, adaptive behavior, sleep, quality of life, caregiver burden, and mood in participants with KCNT1-related epilepsy.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-08-17 |
| Est. Completion | 2023-08-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04924153
The ClinicalTrials.gov registry entry for NCT04924153 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04924153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04924153 about?
NCT04924153 is a clinical study titled "A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy". The primary objective of the study is to characterize seizures in participants with KCNT1-related epilepsy. The secondary objectives are to characterize head growth, symptom severity, neurocognitive and social functions, adaptive behavior, sleep, quality of life, caregiver burden, and mood in partic...
What is the current status of trial NCT04924153?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2021-08-17. Estimated completion is 2023-08-29.
What interventions are being tested in trial NCT04924153?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04924153?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.